Ergomed PLC represents values of innovation, excellence, and integrity. The company is committed to providing high-quality drug development and healthcare services globally. Ergomed's corporate philosophy emphasizes patient-centricity and collaboration with partners to deliver innovative solutions for the pharmaceutical industry. With a focus on scientific expertise and regulatory compliance, Ergomed strives to accelerate the development of new therapies while maintaining the highest ethical standards. As a premier global provider of clinical research and pharmacovigilance services, Ergomed PLC continuously aims to drive improvements in patient outcomes and contribute to the advancement of medical knowledge.

Ergomed PLC is primarily present in various countries and regions worldwide. The company operates across Europe, including in the United Kingdom, Germany, France, Spain, Italy, and Poland, among others. Additionally, Ergomed has a strong presence in the United States, where it conducts its business operations. This multinational pharmaceutical services company has established its footprint in numerous global markets, enabling it to provide a wide range of services to clients across different geographies.

Ergomed PLC has achieved several significant milestones. Firstly, the company successfully completed numerous clinical trials, contributing to the advancement of medical research. Additionally, Ergomed PLC expanded its global presence by establishing strategic partnerships and acquiring other companies in the pharmaceutical sector. The company also achieved financial growth, consistently generating positive revenues and increasing shareholder value. Furthermore, Ergomed PLC received various industry recognitions and awards, reflecting its commitment to excellence in drug development services. These notable milestones highlight Ergomed PLC's leadership and strong market presence in the healthcare industry.

Ergomed PLC is a renowned pharmaceutical services and drug development company. Established in 1997, Ergomed has grown into a global leader in providing specialized solutions to the healthcare industry. With expertise in clinical research, pharmacovigilance, and medical affairs, Ergomed assists pharmaceutical companies in advancing their products through every stage of development. The company's client-focused approach and strategic collaborations have enabled them to successfully support numerous cutting-edge drug development programs. Emphasizing patient safety and regulatory compliance, Ergomed PLC continues to deliver exceptional clinical services to enhance the progress of innovative medical treatments worldwide.

The main competitors of Ergomed PLC in the market are other companies operating in the Contract Research Organization (CRO) industry, such as IQVIA Holdings Inc., ICON plc, and PRA Health Sciences Inc. These companies provide similar services in clinical trial management, pharmacovigilance, and regulatory affairs. However, Ergomed PLC distinguishes itself by offering specialized expertise in orphan drug development and rare diseases. Its unique position in the market allows Ergomed PLC to cater specifically to the needs of pharmaceutical and biotechnology companies working in these niche areas.

Ergomed PLC is primarily active in the pharmaceutical and biotechnology industries.

The business model of Ergomed PLC revolves around providing specialized services to the pharmaceutical industry. As a global company, Ergomed offers a range of solutions including clinical research, pharmacovigilance, and post-approval safety services. By utilizing their expertise and innovative technologies, Ergomed assists pharmaceutical companies in developing and commercializing new drugs safely and efficiently. With a focus on rare diseases and oncology, Ergomed collaborates with partners to design and conduct clinical trials, manage data, analyze results, and ensure compliance with regulatory requirements. Through their comprehensive services, Ergomed PLC contributes to advancing healthcare and improving patient outcomes.

Коефициентът на цена спрямо печалбата (КЦП) на Ergomed е 25,40.

Коефициентът на цена към оборот (KUV) на Ergomed е 3,75.

AlleAktien качественият резултат за Ergomed е 8/10.

очаквана Ergomed оборотът е 183,93 млн. GBP.

очаквана Ergomed печалба е 27,18 млн. GBP.

Ergomed PLC is a global company that specializes in providing clinical services and pharmacovigilance. The company has a diversified portfolio of services and products, which are divided into various divisions. The first division of Ergomed is its core business, the clinical services. Here, the company offers its customers a wide range of services, including budget planning, study design, data management, monitoring, and biometrics. Additionally, Ergomed also provides support to its customers in the submission of applications and regulatory matters. Another division of Ergomed is its pharmacovigilance department. Here, the company offers its customers consultation and support in compliance with pharmacovigilance requirements, monitoring of safety data, and fulfillment of reporting obligations. Furthermore, Ergomed has its own clinical research organization called PrimeVigilance. This offers clinical monitoring, drug risk and safety monitoring, medical review, and training. An important division of Ergomed is its contract research organization (CRO). Here, the company offers its customers support in conducting clinical studies. This includes the design of study protocols, conducting studies, data management and compliance, as well as support in the submission of applications. Ergomed is also involved in drug manufacturing. The company operates its own GMP-compliant manufacturing facility in Amersham, United Kingdom. Here, Ergomed produces drugs for clinical trials as well as on-demand for customers. Another focus of Ergomed is the development of medical devices. The company is working on developing innovative medical devices that enable better patient care and treatment. Overall, Ergomed PLC offers its customers a wide range of services and products, making it an important partner for the pharmaceutical industry. The company specializes in key services that enable its customers to successfully conduct clinical trials and bring drugs safely to the market. Ergomed has extensive industry experience and is committed to always providing innovative solutions to its customers.

Ergomed разпределя дивидента от 0 GBP на плащания годишно.

Дивидентата за Ergomed в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Ergomed е GB00BN7ZCY67.

WKN на Ergomed е A117XM.

Тикерът на Ergomed е ERGO.L.

През последните 12 месеца Ergomed изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Ergomed да изплати дивиденда в размер на 0 GBP.

Дивидентната доходност на Ergomed в момента е .

Ergomed изплаща дивидент на тримесечие. Той се разпределя в месеците .

Ergomed платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 GBP. Това съответства на дивидентна доходност от 0 %.

Ergomed се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Ergomed на 14.09.2024 г. в размер на 0 GBP, трябваше да притежавате акцията в портфейла си преди Ex-деня на 14.09.2024 г..

Последното дивидентно плащане беше извършено на 14.09.2024 г..

През година 2023 Ergomed изплати 0 GBP под формата на дивиденти.

Дивидентите от Ergomed се изплащат в GBP.